Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease

NCT00242008 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00242008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2004
Completion date
July 31, 2005
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease